RESULTS FOR : 'Companion diagnostics'
Showing 1 to 2 of 2 results |    
Keyword Search
Show#
Show#
Results Category/Section
Companion Diagnostics in the pharmaceutical industry part II: business models.

There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools as well as the portent of relevant biological and clinical information that addresses many of the current problems that pharmaceutical companies must overcome. This in concert with the advent of personalised medicine and the demise of the therapeutic drug Blockbuster Model has necessitated a re-evaluation of the pharmaceutical business model.

Overview of Companion Diagnostics in the Pharmaceutical Industry.

Current escalating costs of drug discovery, development and drug launch continue to concern the pharmaceutical sector. This has been compounded by the advent of personalised medicine and its associated demands for individualised products as well as the demise of the blockbuster model.